Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

2012 FDA Advisory Committee Recommendations

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Year-to-date tracking of drug review recommendations from FDA advisory panels, including regulatory actions.

You may also be interested in...



Sun Fights US Charges Over Delays

Sun Pharmaceutical Industries is back before US courts as it contests US antitrust charges filed by plaintiffs over the delayed market entry of generic versions of three major drugs.

GemVax's Novel Peptide For Alzheimer’s Set To Advance After Positive Phase II

GemVax unveils positive topline results for South Korean Phase II study of novel peptide drug targeting patients with moderate to severe Alzheimer’s disease, raising hopes for the upcoming US trials.

QUOTED. 6 December 2019. Jon Speer.

Medical device regulations that were set in place by the US FDA in the 1990s are evolving with the emergence of digital-health products and their iterative nature, medtech consultant Jon Speer says. Check out his comment here.

Topics

UsernamePublicRestriction

Register

PS005194

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel